Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients

Annita Ioanna Gkioka, MD, Aspasia Koudouna, MD, Vasiliki Bartzi, MD, Maria Dimou, MD PhD, Theodoros Iliakis, MD, Aikaterini Bitsani, MD, Vasileios Pardalis, MD, Panayiotis Panayiotidis, MD, Marie-Christine Kyrtsonis, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142006

Published: 2020

Journal Articles

Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece

Maria Dimou, MD PhD, Vasileios Pardalis, MD PhD, Theodoros Iliakis, MD, Aikaterini Bitsani, MD, Ioannis Grafakos, MD, Sotiria Kalyva, PhD, Athanasios Markopoulos, PhD, Marie-Christine Kyrtsonis, MD PhD, Panayiotis Panayiotidis, MD

Blood (2019) 134 (Supplement_1): 3429.

https://doi.org/10.1182/blood-2019-122834

Published: 2019

Journal Articles

Uninvolved Immunoglobulin Suppression Determined By "Hevylite" ASSAY. Strongly Predicts Evolution of Smoldering Myeloma (SMM) to Symptomatic Multiple Myeloma (MM)

Paraskevi Papaioannou, MD, Annita Ioanna Gkioka, MD, Kallirroi Tsalimalma, MD, Aspasia Koudouna, MD, Anastasia Kopsaftopoulou, MD, Konstantina Chamoulkou, MD, Ioannis Grafakos, MD, Aikaterini Bitsani, MD, Theodoros Iliakis, MD, Maria Dimou, MD PhD, Nikolitsa Kafassi, MD, Petros Sfikakis, MD PhD, Panayiotis Panayiotidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD

Blood (2018) 132 (Supplement 1): 5584.

https://doi.org/10.1182/blood-2018-99-118631

Published: 2018

Journal Articles

Increased SERUM VON Willebrand Levels in Chronic Lymphocytic Leukemia (CLL) Patients Are Related to a Shorter Time to Treatment

Thommais Tryfou, MLS, Paraskevi Papaioannou, MD, Panagiotis Repousis, MD, Annita Ioanna Gkioka, MD, Sotirios Sachanas, Aikaterini Bitsani, MD, Maria Dimou, MD PhD, Dimitrios Maltezas, Aspasia Koudouna, MD, Anastasia Kopsaftopoulou, MD, Konstantina Chamoulkou, MD, Ioannis Grafakos, MD, Styliani Kokori, MD, Argyrios Tsantes, MD, Gerasimos Pangalis, MD, Panayiotis Panayiotidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD

Blood (2018) 132 (Supplement 1): 5547.

https://doi.org/10.1182/blood-2018-99-119520

Published: 2018

Journal Articles

Study of MGUS-Series: Disease Evolution, Coexistant Disorders and Other Clinical Observations

Dimitrios Maltezas, MD, Nikolaou Eftychia, MD, Paraskevi Papaioannou, MD, Aikaterini Bitsani, MD, Tatiana Tzenou, MD, Maria Dimou, MD, Theodoros Iliakis, MD, Sotiria Kotsanti, MD, Panagiota Petsa, MD, Panayiotis Panayiotidis, Marie-Christine Kyrtsonis, MD

Blood (2015) 126 (23): 5323.

https://doi.org/10.1182/blood.V126.23.5323.5323

Published: 2015

NARROW

Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients

Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece

Uninvolved Immunoglobulin Suppression Determined By "Hevylite" ASSAY. Strongly Predicts Evolution of Smoldering Myeloma (SMM) to Symptomatic Multiple Myeloma (MM)

Increased SERUM VON Willebrand Levels in Chronic Lymphocytic Leukemia (CLL) Patients Are Related to a Shorter Time to Treatment

Study of MGUS-Series: Disease Evolution, Coexistant Disorders and Other Clinical Observations

Email alerts

ASH Publications

American Society of Hematology

Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients

Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece

Uninvolved Immunoglobulin Suppression Determined By "Hevylite" ASSAY. Strongly Predicts Evolution of Smoldering Myeloma (SMM) to Symptomatic Multiple Myeloma (MM)

Increased SERUM VON Willebrand Levels in Chronic Lymphocytic Leukemia (CLL) Patients Are Related to a Shorter Time to Treatment

Study of MGUS-Series: Disease Evolution, Coexistant Disorders and Other Clinical Observations

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only